 |
|
Controlled Pilot Trial of Monthly Intravenous Cyclophosphamide in Multiple Sclerosis
James M. Killian, MD;
Robert B. Bressler, MD;
Richard M. Armstrong, MD;
David P. Huston, MD
Arch Neurol. 1988;45(1):27-30.
Abstract
• Monthly intravenous cyclophosphamide treatment was compared with placebo treatment for one year in a controlled trial of 14 patients with relapsing/remitting multiple sclerosis. Eight patients received placebo and six patients received cyclophosphamide. The cyclophosphamide group showed a definite trend to have less frequent and less prolonged episodes than the placebo group. When each group served as their own controls, the cyclophosphamide group had a significant decrease in episodes while the placebo group did not. When the placebo group was then given cyclophosphamide, they also had a significant decrease in episodes. When all patients who were receiving cyclophosphamide were combined for analysis, the decrease in episodes was even more evident. Complications were minimal. These results suggest that monthly intravenous doses of cyclophosphamide may influence the frequency and duration of episodes of relapsing/remitting multiple sclerosis.
Author Affiliations
From the Departments of Neurology (Drs Killian and Armstrong), Medicine (Drs Bressler and Huston), and Microbiology and Immunology (Dr Huston), Baylor College of Medicine and the Methodist Hospital, Houston.
Footnotes
Accepted for publication Sept 18, 1987.
Reprint requests to the Methodist Hospital, Neurosensory Center, MS NB 302, 6501 Fannin, Houston, TX 77030 (Dr Killian).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Krishnan et al.
Arch Neurol 2008;65:1044-1051.
ABSTRACT
| FULL TEXT
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
Weiner and Cohen
Mult Scler 2002;8:142-154.
ABSTRACT
Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?
Bryant et al.
J. Neurol. Neurosurg. Psychiatry 2001;70:574-579.
ABSTRACT
| FULL TEXT
Treatment of progressive multiple sclerosis with pulse cyclophosphamidel methylprednisolone: Response to therapy is linked to the duration of progressive disease
Hohol et al.
Mult Scler 1999;5:403-409.
ABSTRACT
Side-effects of intravenous cyclophosphamide pulse therapy
Martin et al.
Lupus 1997;6:254-257.
ABSTRACT
|
